Andrew Newland, chief executive of ANGLE PLC (), discusses with Proactive their significant new collaboration with healthcare giant .
The two will be working on a metastatic breast cancer study.
Abbott will provide its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridization) analysis of circulating tumour cells (CTCs) in the form of a research grant.
FISH analysis, which is a form of investigation of the cancer cells used with solid tissue biopsy to help select treatment, is one of the exploratory end-points for ANGLE's FDA study in metastatic breast cancer
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE